A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
GA Depot
Recommended Posts
- I’m going to be more open about my invisible scars from MS
- Having parents who smoked increases risk of pediatric MS: Study
- Ocrevus and Tysabri appear to work equally well to control relapsing MS
- MS-related bladder issues are unpredictable and disruptive
- Dementia risk nearly fivefold higher for people with multiple sclerosis: Study